Decrease of valproate-induced hyperammonemia in normal subjects by lipid ingestion

J Neurol Sci. 1985 Jul;69(3):285-90. doi: 10.1016/0022-510x(85)90140-6.

Abstract

Sodium valproate (VPA), a branched short-chain fatty acid, always causes a hyperammonemia of renal origin in fasting man. The intake of medium-length, straight-chain fatty acids abolishes the VPA-induced hyperammonemia, and VPA free fraction increases concomitantly. Accordingly, fatty acids could be useful in preventing and treating hyperammonemia-accompanied stuporous states which are complications of VPA medication.

MeSH terms

  • Ammonia / blood*
  • Dietary Fats / therapeutic use*
  • Fatty Acids / therapeutic use*
  • Humans
  • Kidney Diseases / blood
  • Kidney Diseases / chemically induced*
  • Kidney Diseases / diet therapy
  • Male
  • Valproic Acid / antagonists & inhibitors*
  • Valproic Acid / blood

Substances

  • Dietary Fats
  • Fatty Acids
  • Valproic Acid
  • Ammonia